NCT02975388View on ClinicalTrials.gov

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

July 6, 2017

Study Completion Date

July 6, 2017

Conditions

Renal Impairment

Interventions

DRUG

RO7079901

Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.

Trial Locations (5)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Inc., Miami

37920

New Orleans Center for Clinical Research, Knoxville

55114

Prism Clinical Research, Saint Paul

55404

DaVita Clinical Research, Minneapolis

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02975388 - A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901 | Biotech Hunter | Biotech Hunter